Knight Therapeutics (TSX:GUD) announced the Canadian launch of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine subdermal implant of buprenorphine hydrochloride for the management of opioid dependence in patients...
An Oct. 26 article on the Washington Post web site discusses job openings in Canada’s legalized cannabis sector, highlighting an Ontario government policy advisor who left his job to join Lobo Genetics as its director...
Closely-held Mati Therapeutics’ international patent portfolio has grown to 114 issued patents, including a recently granted U.S. patent, which covers a drug delivery system for administering an ophthalmic drug through...
Closely-held Scientus Pharma received Health Canada authorization to produce cannabis soft gel capsules and oils at its state-of-the-art commercial production facility in Whitby, Ontario. “At Scientus Pharma, our main...
In the latest edition of Scientific American online, Dr. Gina Siddiqui, an emergency room doctor at Yale New Haven Hospital, discusses why physicians have incorrectly feared that new technology would make their jobs...
Ortho Regenerative Technologies (CSE:ORTH) presented a poster entitled, “Freeze-dried [Ortho-R] in Platelet-rich Plasma in Sheep Model of Rotator Cuff Repair,” at the SICOT Orthopaedic World Congress in Montreal. The...
CHF Solutions (NASDAQ:CHFS) and NI Medical are collaborating to explore potential clinical synergies between CHF’s Aquadex FlexFlow System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume...
IntelGenx’s (TSXV:IGX; OTCQX:IGXT) partner, Insud Pharma (formerly Chemo Group), submitted an abbreviated new drug application (ANDA) with the FDA for a generic buccal film product. “The filing of an ANDA for this...
BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the second stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the...
IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that patient recruitment would begin for a Phase 2a study with Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s Disease (AD). Two research sites in Toronto...